SCHEMBL6844260

SCHEMBL6844260

OC(CN1CCN(Cc2ccc3c(c2)OCO3)CC1)Cn1cnc2ccccc21

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.60
LMNA P02545 3/20 0.56
HTT P42858 2/20 0.54
KMT2A Q03164 5/20 0.54
MEN1 O00255 4/20 0.54
SMN1; SMN2 Q16637 2/20 0.53
GAA P10253 3/20 0.53
ALDH1A1 P00352 2/20 0.53
USP2 O75604 2/20 0.53
MAPT P10636 2/20 0.53
RAB9A P51151 1/20 0.53
TSHR P16473 2/20 0.53
POLB P06746 1/20 0.52
CYP1A2 P05177 2/20 0.51
CYP3A4 P08684 2/20 0.51
CYP2D6 P10635 2/20 0.51
CYP2C19 P33261 2/20 0.51
CYP2C9 P11712 1/20 0.51
ALOX15 P16050 1/20 0.51
HTR1A P08908 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6844242 0.83 LMNA (0.60) KDM4ELMNAHTTSMN1; SMN2GAA
SCHEMBL8665363 0.81 HTT (0.59) KDM4ELMNAHTTSMN1; SMN2GAA
SCHEMBL1304932 0.80 LMNA (0.67) KDM4ELMNAHTTKMT2AMEN1
SCHEMBL7267761 0.76 KDM4E (0.65) KDM4ELMNAHTTKMT2AMEN1
SCHEMBL8340692 0.74 AGER (0.60) LMNAHTTSMN1; SMN2GAAALDH1A1
SCHEMBL6843887 0.74 AGER (0.49) KDM4ELMNAKMT2AMEN1GAA
SCHEMBL8336875 0.74 AGER (0.54) KDM4ELMNAHTTSMN1; SMN2GAA
SCHEMBL6843574 0.74 HTT (0.59) LMNAHTTSMN1; SMN2GAAMAPT
SCHEMBL6843591 0.74 ADRA1D (0.50) LMNAALDH1A1MAPTCYP2D6CYP2C19
SCHEMBL609438 0.74 MEN1 (0.63) KDM4ELMNAHTTKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0775118-B1 BENZIMIDAZOLE DERIVATIVES HAVING DOPAMINERGIC ACTIVITY PFIZER (US) 2003-06-04 EP claimed
US-20040116443-A1 Dopamine D4 ligands for the treatment of novelty-seeking disorders PFIZER INC 2004-06-17 US disclosed
US-20030158208-A1 Dopamine D4 ligands for the treatment of novelty-seeking disorders PFIZER INC. 2003-08-21 US disclosed
EP-0775118-B1 BENZIMIDAZOLE DERIVATIVES HAVING DOPAMINERGIC ACTIVITY PFIZER (US) 2003-06-04 EP disclosed
US-6548502-B2 Preventing disorder selected from pathological gambling, attention deficit disorder with hyperactivity disorder, substance addiction such as drug and alcohol and sex in a mammals by administering pyrido(1,2-a) pyrazine derivatives PFIZER INC 2003-04-15 US disclosed
US-20020049209-A1 Dopamine D4 ligands for the treatment of novelty-seeking disorders PFIZER INC. 2002-04-25 US disclosed
EP-1177792-A2 Dopamine D4 Ligands for the treatment of novelty-seeking disorders Pfizer Products Inc. (US) 2002-02-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020049209-A1 Dopamine D4 ligands for the treatment of novelty-seeking disorders SLC6A3, DRD4, DRD2 KDM4E 1116/4885LMNA 4884/4885HTT 1366/4885
US-20030158208-A1 Dopamine D4 ligands for the treatment of novelty-seeking disorders SLC6A3, DRD4, DRD2 KDM4E 1116/4885LMNA 4884/4885HTT 1366/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.